This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical



Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact



DosingEfficacy & Safety DataEfficacy &
Safety Data
EfficacyPrevention of Postmenopausal OsteoporosisSafety Profile
Prescribing Information, including BOXED WARNINGPatient InformationIndicationsPatient Site
Help patients find relief

Premarin® (conjugated estrogens tablets):

For the treatment of moderate to severe hot flashes due to menopause

Live Pfizer Connect Health & Science Representatives 

Personalized support and resources,  
call 1-833-WMN-HLTH
(1-833-966-4584) 9 AM - 7 PM ET

Call NowLoading
No generic equivalent

Premarin contains a mixture of conjugated estrogens and is offered in 5 dosage strengths to help meet patients’ individual needs1

See Dosage StrengthsLoading
Hot flash relief for your appropriate patients

Premarin provides significant reduction in the frequency and severity of moderate to severe hot flashes due to menopause1

View Efficacy DataLoading
Access, Samples, and SavingsCost and Coverage

Find Premarin coverage information in your area.

Check Coverage In Your AreaLoading
Samples eligibility

Samples may be available for your practice.

Check Sample Eligibility Loading
Savings for eligible patients

Co-pay assistance may be available*

Download the Savings CardLoadingReferences*Terms & Conditions apply. See below.
Resources for you and
your patients

View materials for you and your patients


Find videos and on-demand webinars


1. Premarin. Prescribing information. Pfizer; 2024.

SAVINGS CARD TERMS AND CONDITIONSBy using this Premarin Co-Pay Card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:  SAVINGS CARD TERMS AND CONDITIONS
  • Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
  • Patient must have private insurance. Offer is not valid for cash paying patients. The value of this Co-Pay Card is limited to $55 per use or the amount of your co-pay, whichever is less.
  • Maximum savings of $660 per calendar year.
  • This Co-Pay Card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
  • You must deduct the value of this Co-Pay Card from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
  • You are responsible for reporting use of the [coupon/co-pay card] to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the Co-Pay Card, as may be required. You should not use the Co-Pay Card if your insurer or health plan prohibits use of manufacturer Co-Pay Card.
  • You must be 18 years of age or older to redeem the Co-Pay Card.
  • This Co-Pay Card is not valid where prohibited by law.
  • The benefit under the Co-Pay Card program is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either.
  • Co-Pay Card cannot be combined with any other external savings, free trial or similar offer for the specified prescription (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator” or “maximizer” programs)
  • Third party payers, pharmacy benefit managers, or the agents of either, are prohibited from assisting patients with enrolling in the Co-Pay Card program.
  • Co-Pay Card will be accepted only at participating pharmacies.
  • If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer. [include for coupon/co-pay card where rebate offer is available]
  • This Co-Pay Card is not health insurance.
  • Offer good only in the U.S. and Puerto Rico.
  • Co-Pay Card is limited to 1 per person during this offering period and is not transferable.
  • A Co-Pay Card may not be redeemed more than once per 30 days per patient.
  • No other purchase is necessary.
  • Data related to your redemption of the Co-Pay Card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other Co-Pay Card redemptions and will not identify you.
  • Pfizer reserves the right to rescind, revoke or amend this offer without notice.
  • Offer expires 12/31/2025 
SAVINGS CARD TERMS AND CONDITIONSFor reimbursement when using a nonparticipating pharmacy/mail order:
Pay for Premarin prescription and mail copy of original pharmacy receipt (cash register receipt NOT valid) with product name, date, and amount circled to: Pfizer, Attn: Claims Processing Department, IQVIA, Inc., 77 Corporate Drive, Bridgewater, NJ 08807. Be sure to include a copy of the front of your co-pay card, your name, and mailing address.

For help with the Premarin Co-Pay Card, call 1-866-410-3700.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. PP-MCL-USA-0367

INDICATIONSPremarin® (conjugated estrogens tablets) is indicated in the treatment of moderate to severe vasomotor symptoms due to menopause and the prevention of postmenopausal osteoporosis.When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered.
Important Safety Information

There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding. 

Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia.

The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women with daily oral conjugated estrogens (CE) 0.625mg alone relative to placebo. The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism, stroke, and myocardial infarction in postmenopausal women with daily oral CE 0.625mg combined with medroxyprogesterone acetate (MPA) 2.5mg relative to placebo. 

The WHI Memory Study (WHIMS) reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older, in both the estrogen alone and estrogen plus progestin arms. It is unknown whether these findings apply to younger postmenopausal women.

The WHI estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer.

In the absence of comparable data, these risks should be assumed to be similar for other doses of CE or CE and MPA, and other dosage forms of estrogens or combinations and dosage forms of estrogens and progestins. 

Estrogens with or without progestins should be prescribed at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman.

Premarin should not be used in women with any of the following conditions: undiagnosed abnormal genital bleeding; known, suspected, or a history of breast cancer; known or suspected estrogen-dependent neoplasia; active deep vein thrombosis, pulmonary embolism, or a history of these conditions; active arterial thromboembolic disease (e.g., stroke, myocardial infarction), or a history of these conditions; anaphylactic reaction or angioedema with Premarin; liver impairment or disease; thrombophilic disorders; pregnancy.

Consistent with the WHI clinical trials, observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use. One large meta-analysis of prospective cohort studies reported increased risks that were dependent upon duration of use and could last up to >10 years after discontinuation of estrogen plus progestin therapy and estrogen-alone therapy. Extension of the WHI trials also demonstrated increased breast cancer risk associated with estrogen plus progestin therapy.

The WHI estrogen plus progestin sub-study reported a statistically non-significant increased risk of ovarian cancer. A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown.

Estrogens increase the risk of gallbladder disease. Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs. Monitor thyroid function in women on thyroid replacement therapy, because estrogens may be associated with increased thyroid binding globulin (TBG) levels.

Most common adverse reactions (≥ 5 percent) are abdominal pain, asthenia, pain, back pain, headache, flatulence, nausea, depression, insomnia, breast pain, endometrial hyperplasia, leucorrhea, vaginal hemorrhage, and vaginitis.

IndicationsPremarin is indicated in the treatment of moderate to severe vasomotor symptoms due to menopause and the prevention of postmenopausal osteoporosis.

When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered.

Please see full Prescribing Information, including BOXED WARNING and Patient Information.